Colgate-Palmolive Company (CL) Stock Forecast
Data as of May 2, 2026Consumer Defensive · Current price $86.84 (+1.76%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Lauren Lieberman | Barclays | $79.00 | -9.0% |
| Apr 8, 2026 | Chris Carey | Wells Fargo | $92.00 | +5.9% |
| Feb 20, 2026 | Bonnie Herzog | Goldman Sachs | $100.00 | +15.2% |
| Feb 3, 2026 | Lauren Lieberman | Barclays | $88.00 | +1.3% |
| Feb 2, 2026 | Dara Mohsenian | Morgan Stanley | $100.00 | +15.2% |
| Jan 31, 2026 | Bonnie Herzog | Goldman Sachs | $94.00 | +8.2% |
| Jan 16, 2026 | Lauren Lieberman | Barclays | $83.00 | -4.4% |
| Jan 14, 2026 | Peter Grom | UBS | $93.00 | +7.1% |
| Nov 3, 2025 | Robert Ottenstein | Evercore ISI | $94.00 | +8.2% |
| Nov 3, 2025 | Dara Mohsenian | Morgan Stanley | $87.00 | +0.2% |
| Oct 1, 2025 | Lauren Lieberman | Barclays | $82.00 | -5.6% |
| Sep 23, 2024 | Korinne Wolfmeyer | Piper Sandler | $121.00 | +39.3% |
| Sep 16, 2024 | Chris Carey | Wells Fargo | $100.00 | +15.2% |
| Jul 22, 2024 | Mark Astrachan | Stifel Nicolaus | $105.00 | +20.9% |
| May 28, 2024 | Dara Mohsenian | Morgan Stanley | $103.00 | +18.6% |
| May 15, 2024 | Chris Graja | Argus Research | $107.00 | +23.2% |
| Apr 29, 2024 | Steve Powers | Deutsche Bank | $98.00 | +12.9% |
| Apr 29, 2024 | Mark Astrachan | Stifel Nicolaus | $95.00 | +9.4% |
| Apr 10, 2024 | Mark Astrachan | Stifel Nicolaus | $94.00 | +8.2% |
| Apr 8, 2024 | Robert Ottenstein | Evercore ISI | $96.00 | +10.5% |
Top Analysts Covering CL
CL vs Sector & Market
| Metric | CL | Consumer Defensive Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.31 | 2.55 | 2.41 |
| Analyst Count | 35 | 12 | 18 |
| Target Upside | +7.9% | +1188.8% | +14.9% |
| P/E Ratio | 33.09 | -7.43 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $21.08B | $21.30B | $21.48B | 14 |
| 2027-03-31 | $5.35B | $5.38B | $5.43B | 4 |
| 2027-06-30 | $5.45B | $5.48B | $5.53B | 4 |
| 2027-09-30 | $5.45B | $5.48B | $5.53B | 5 |
| 2027-12-31 | $5.55B | $5.58B | $5.64B | 4 |
| 2028-03-31 | $5.54B | $5.57B | $5.62B | 3 |
| 2028-06-30 | $5.63B | $5.66B | $5.72B | 3 |
| 2028-09-30 | $5.63B | $5.66B | $5.71B | 5 |
| 2028-12-31 | $5.74B | $5.77B | $5.82B | 3 |
| 2029-12-31 | $23.14B | $23.43B | $23.74B | 5 |
| 2030-12-31 | $23.76B | $24.06B | $24.38B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.74 | $3.82 | $3.89 | 11 |
| 2027-03-31 | $0.97 | $0.98 | $0.99 | 4 |
| 2027-06-30 | $1.00 | $1.01 | $1.02 | 5 |
| 2027-09-30 | $0.98 | $0.99 | $1.00 | 8 |
| 2027-12-31 | $1.04 | $1.05 | $1.06 | 4 |
| 2028-03-31 | $1.04 | $1.04 | $1.06 | 5 |
| 2028-06-30 | $1.07 | $1.08 | $1.10 | 7 |
| 2028-09-30 | $1.06 | $1.06 | $1.08 | 10 |
| 2028-12-31 | $1.13 | $1.14 | $1.15 | 5 |
| 2029-12-31 | $4.60 | $4.67 | $4.75 | 2 |
| 2030-12-31 | $4.78 | $4.85 | $4.94 | 2 |
Frequently Asked Questions
What is the analyst consensus for CL?
The consensus among 35 analysts covering Colgate-Palmolive Company (CL) is Buy with an average price target of $92.45.
What is the highest price target for CL?
The highest price target for CL is $121.00, set by Korinne Wolfmeyer at Piper Sandler on 2024-09-23.
What is the lowest price target for CL?
The lowest price target for CL is $76.00, set by Christopher Carey at Wells Fargo on 2022-01-31.
How many analysts cover CL?
35 analysts have issued ratings for Colgate-Palmolive Company in the past 12 months.
Is CL a buy or sell right now?
Based on 35 analyst ratings, CL has a consensus rating of Buy (2.31/5) with a +7.9% upside to the consensus target of $92.45.
What are the earnings estimates for CL?
Analysts estimate CL will report EPS of $3.82 for the period ending 2026-12-31, with revenue estimated at $21.30B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.